专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2012018632A3 ANALYTE SENSOR 审中-公开
公开(公告)号：WO2012018632A3
公开(公告)日：2012-02-09
申请号：PCT/US2011/045385
申请日：2011-07-26
申请人： SENOVA SYSTEMS, INC. , LEE, Eric , MICKLATCHER, Mark
发明人： LEE, Eric , MICKLATCHER, Mark
IPC分类号： G01N27/26 , G01N27/30
摘要： Matrix materials, such as sol-gels and polymers derivatives to contain a redox active material can be used to form electrodes and probes suitable for use in pH meters and other analyte sensing devices.

52. 发明申请

WO2011143460A2 SYSTEM AND METHODS FOR REMOVING A LOOSE TOOTH 审中-公开
标题翻译：用于去除松散牙齿的系统和方法
公开(公告)号：WO2011143460A2
公开(公告)日：2011-11-17
申请号：PCT/US2011/036299
申请日：2011-05-12
申请人： CRANE, Colton
发明人： CRANE, Colton
IPC分类号： A61C3/14 , A61C3/00 , A61C19/00
CPC分类号： A61C3/14 , Y10T29/49826
摘要： A device for removing a loose tooth, the device including a handle, a base structure, and a retention strap, wherein the retention strap is secured about an outer surface of the loose tooth such that the base structure forms an interface with the tooth. The device further including features for increasing friction between the base structure and the tooth to prevent slippage while removing the tooth with the device.
摘要翻译：一种用于去除松动牙齿的装置，该装置包括手柄，基部结构和保持带，其中保持带围绕松散牙齿的外表面固定，使得基部结构形成与牙齿的界面。该装置还包括用于增加基部结构和齿之间的摩擦的特征，以防止在用该装置移除牙齿的同时滑动。

53. 发明申请

WO2010111531A9 DEVICE FOR DETECTING AN ANALYTE 审中-公开
公开(公告)号：WO2010111531A9
公开(公告)日：2010-09-30
申请号：PCT/US2010/028726
申请日：2010-03-25
申请人： SENOVA SYSTEMS, INC. , LEONARD, Lee , DUIMSTRA, Joseph A. , LEE, Eric , MICKLATCHER, Mark , SIMONYI, Victor , WILDGOOSE, Greg , KETO, Joseph I. , SEIDEL, Anton
发明人： LEONARD, Lee , DUIMSTRA, Joseph A. , LEE, Eric , MICKLATCHER, Mark , SIMONYI, Victor , WILDGOOSE, Greg , KETO, Joseph I. , SEIDEL, Anton
IPC分类号： G01N27/30 , G01N27/416 , G01N33/18 , G01N27/26
摘要： Devices for detecting an analyte comprising a redox active analyte sensitive material on a working electrode and computer assisted signal acquisition and processing.

54. 发明申请

WO2010104962A1 DEVICE FOR PROVIDING A MEANS FOR INTERNAL CALIBRATION IN AN ELECTROCHEMICAL SENSOR 审中-公开
标题翻译：在电化学传感器中提供内部校准的手段的装置
公开(公告)号：WO2010104962A1
公开(公告)日：2010-09-16
申请号：PCT/US2010/026842
申请日：2010-03-10
申请人： SENOVA SYSTEMS, INC. , DUIMSTRA, Joseph, A. , LEONARD, Lee , WILDGOOSE, Gregory, G. , LEE, Eric
发明人： DUIMSTRA, Joseph, A. , LEONARD, Lee , WILDGOOSE, Gregory, G. , LEE, Eric
IPC分类号： G01N27/30 , G01N27/26
CPC分类号： G01N27/302 , B82Y30/00 , C25B11/00 , G01N27/301 , G01N27/333 , G01N27/36 , Y10S977/742
摘要： Internally calibrated pH and other analyte sensors based on redox agents provide more accurate results when the redox active reference agent is in a constant chemical environment, yet separated from the solution being analyzed in such a way as to maintain electrical contact with the sample. Room temperature ionic liquids (RTIL) can be used to achieve these results when used as a salt bridge between the reference material and the sample being analyzed. The RTIL provides the constant chemical environment and ionic strength for the redox active material (RAM) and provides an electrolytic layer that limits or eliminates direct chemical interaction with the sample. A broad range of RAMs can be employed in a variety of configurations in such "Analyte Insensitive Electrode" devices.
摘要翻译：当氧化还原活性参考试剂处于恒定的化学环境中时，内部校准的pH值和其它基于氧化还原剂的分析物传感器可提供更精确的结果，但与被分析的溶液分离，以保持与样品的电接触。当用作参考物质和正在分析的样品之间的盐桥时，室温离子液体（RTIL）可用于实现这些结果。 RTIL为氧化还原活性材料（RAM）提供恒定的化学环境和离子强度，并提供限制或消除与样品的直接化学相互作用的电解质层。在这种“分析物不敏感电极”装置中，可以采用各种各样的配置的宽范围的RAM。

55. 发明申请

WO2022236067A1 IMPLANTABLE MEDICAL LEAD AND RELATED DEVICES AND METHODS 审中-公开
公开(公告)号：WO2022236067A1
公开(公告)日：2022-11-10
申请号：PCT/US2022/028089
申请日：2022-05-06
申请人： FORESITE CAPITAL HOLDINGS, LLC
发明人： OBRAY, Jon , OBRAY, Rick , OLSON, Eric
IPC分类号： A61N1/05
摘要： An implantable medical lead for electrical stimulation may include a body, which may include a flexible distal end, a flexible proximal end, and a rigid portion extending between the flexible distal end and the flexible proximal end. The body may include an aperture extending through the flexible distal end and the flexible proximal end and configured to receive a guidewire therethrough. The implantable medical lead may include an electrode coupled to the rigid portion and an electrical conductor electrically connected to the electrode and extending from the electrode through the flexible proximal end. A medical anchor to secure the implantable medical lead may include a body and a clamp element configured to move between an open position and a closed position. A surgical instrument to implant the implantable medical lead may include a first arm having a first clamp surface and a second arm having a second clamp surface.

56. 发明申请

WO2022187642A1 COMPOSITIONS AND METHODS FOR IMPROVING BRAIN FUNCTION 审中-公开
公开(公告)号：WO2022187642A1
公开(公告)日：2022-09-09
申请号：PCT/US2022/018935
申请日：2022-03-04
申请人： HEALTH VIA MODERN NUTRITION INC.
发明人： WOO, Geoffrey Hubert , MANSOR, Latt Shahril , ENSLEY, Christine
IPC分类号： A61K31/352 , A23L2/38 , A61K2300/00
摘要： Brain function may be improved by administering a therapeutically effective amount of 1,3-butanediol, selected from R-1,3-butanediol, S-1,3-butanediol, and racemic 1,3-butanediol, in combination with a therapeutically effective amount of cannabidiol (CBD). The disclosed compositions include synergistically effective amounts of 1,3-butanediol in combination with a synergistically effective amount of cannabidiol (CBD). The compositions may be administered to a subject for treating anxiety, concussion, traumatic brain injury (TBI), and/or cognitive impairment.

57. 发明申请

WO2022169852A1 COMPOSITIONS AND METHODS FOR IMPROVING RELAXATION, SLEEP, COGNITION, AND/OR PHYSICAL PERFORMANCE 审中-公开
公开(公告)号：WO2022169852A1
公开(公告)日：2022-08-11
申请号：PCT/US2022/014916
申请日：2022-02-02
申请人： HEALTH VIA MODERN NUTRITION INC.
发明人： WOO, Geoffrey Hubert , MANSOR, Latt Shahril , ENSLEY, Christine
IPC分类号： A61K31/047 , A61K31/522 , A61P25/00 , A61P25/24 , A61P25/28
摘要： The present invention comprises compositions and methods for improving relaxation, sleep, cognition, and/or physical performance. Compositions may include therapeutically effective amounts of 1,3-butanediol, in the form of R-1,3-butanediol, S-1,3-butanediol, or racemic 1,3-butanediol, in combination with a therapeutically effective amount of one or more additional active ingredients selected from caffeine, L-theanine, and a mixture of caffeine and L-theanine. Compositions may further include synergistically effective amounts of 1,3-butanediol, in the form of R-1,3-butanediol, S-1,3-butanediol, or racemic 1,3-butanediol, in combination with a synergistically effective amount of caffeine, L-theanine, or a mixture of caffeine and L-theanine.

58. 发明申请

WO2020061503A1 METHODS AND COMPOSITIONS FOR PRODUCING HOMOKARYOTIC FILAMENTOUS FUNGAL CELLS 审中-公开
公开(公告)号：WO2020061503A1
公开(公告)日：2020-03-26
申请号：PCT/US2019/052238
申请日：2019-09-20
申请人： PERFECT DAY, INC.
发明人： GEISTLINGER, Timothy , DARST, Brian , SCHUERG, Timo , RAMESH, Balakrishnan , YODER, Wendy
IPC分类号： C07H21/00 , C12N1/14 , C12N1/15 , C12N3/00 , C12N9/00 , C12N9/88 , C12N15/09
摘要： Provided are methods and compositions useful for producing filamentous fungal cells and compounds produced by such cells that have utility in a variety of applications. In one aspect, provided herein is a method for producing a SLR from a filamentous fungal cell, wherein the method comprises the steps of: a) growing the filamentous fungal cell in a first medium comprising a first carbon source to obtain an actively growing mycelial culture, and b) replacing the first medium of the actively growing mycelial culture with a second medium comprising a second carbon source to induce production of the SLR; wherein the first carbon source comprises a metabolizable carbon compound, wherein the second carbon source comprises only non-metabolizable carbon compounds, and wherein the second medium comprises no other carbon source than the second carbon source.

59. 发明申请

WO2017205420A1 AQUAPONICS SYSTEM 审中-公开
标题翻译： AQUAPONICS系统
公开(公告)号：WO2017205420A1
公开(公告)日：2017-11-30
申请号：PCT/US2017/034064
申请日：2017-05-23
申请人： BURROWS, Ken B. , NOEL, D. Brent
发明人： BURROWS, Ken B. , NOEL, D. Brent
IPC分类号： A01G31/02
摘要： An aquaponics system for growing plants may include a tank configured to hold at least one aquatic animal species and nutrient-rich water. The tank may include an outlet pipe and an inlet pipe. The outlet pipe may branch into a first and second delivery pipe. The aquaponics system may include first and second upper-level growth media bins and first and second lower-level float bins. The first and second delivery pipes may deliver the nutrient-rich water to the first and second upper-level growth media bins, respectively. The first and second lower-level float bins may receive the nutrient-rich water from the first and second upper-level growth media bins, respectively.
摘要翻译：用于种植植物的aquaponics系统可包括配置为容纳至少一种水生动物物种和富含营养物的水的罐。该罐可以包括出口管和入口管。出口管可以分支成第一和第二输送管。该aquaponics系统可能包括第一个和第二个上层增长媒体箱和第一个和第二个下层浮动箱。第一输送管和第二输送管可以分别将富营养水输送到第一和第二上层生长培养基箱。第一和第二下层浮箱可以分别接收来自第一和第二上层生长介质箱的富含营养的水。

60. 发明申请

WO2016191394A1 TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONISTS 审中-公开
标题翻译：用GLP-1拮抗剂治疗后脑血栓形成
公开(公告)号：WO2016191394A1
公开(公告)日：2016-12-01
申请号：PCT/US2016/033836
申请日：2016-05-23
申请人： THE BOT OF THE LELAND STANFORD JUNIOR UNIVERSITY
发明人： MCLAUGHLIN, Tracey L. , CRAIG, Colleen M.
IPC分类号： A61K38/17 , A61P3/10
CPC分类号： A61K38/2278 , A61K9/0019 , A61K9/08 , A61K9/10 , A61K38/17 , A61K38/22 , A61K38/26 , A61K45/06 , A61P3/08
摘要： Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.
摘要翻译：高胰岛素血症低血糖的治疗包括单独施用有效量的胰高血糖素样肽-1受体拮抗剂（GLP1RA）或与胰岛淀粉样多肽模拟剂或任何抗胃排空剂组合。肥胖手术后患有高胰岛素血症的患者特别受益，因为目前尚无有效的治疗方法。预防或减少餐后低血糖症状，如心悸，震颤，虚弱，出汗，混乱，疲劳，视力模糊，癫痫发作或意识丧失等急性不良反应，以及预防高胰岛素血症低血糖的慢性不良反应，如认知障碍，可以通过用GLP1RA处理来实现。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式